Alvimopan dihydrate

Overview

Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC 50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor ( K i =0.47 nM) over κ- and δ-opioid receptors ( K i s=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus.

Application

Products | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pain | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Obesity | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Coronavirus Infection | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Opioid Receptor

Product Information

• Catalog No.: HY-76657A
• CAS No.: 170098-38-1
• Molecular Formula: C25H36N2O6
• Molecular Weight: 460.56
• Purity: 98.66%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (5.43 mM); Clear solution
• Availability: In-stock

Source

Original product source